AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26445075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 610
Study 26445075 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 1.25 mg
Number of subjects: 610
Study 26445075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment regimen
Number of subjects: 610
Study 26445075 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous treatment regimen
Number of subjects: 610
Study 26445075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610
Study 26445075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ranibizumab
Number of subjects: 610
Study 26445075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bevacizumab
Number of subjects: 610
Study 22995972 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid
Number of subjects: 0
Study 22995972 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 20 mg bid
Number of subjects: 0
Study 22995972 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 30 mg bid
Number of subjects: 0
Study 22995972 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 21296118 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal and meningococcal serogroup C conjugate vaccine (9vPnC‐MnCC)
Number of subjects: 467
Study 21296118 — intervention group
Group type: COMPARATOR
Intervention: 9-valent pneumococcal conjugate vaccine (9vPnC)
Number of subjects: 467
Study 19293355 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium, 120 microg daily for 8 weeks
Number of subjects: 100
Study 17852714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Hygiene Training (VH)
Number of subjects: 37
Study 17852714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 37
Study 17852714 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 37
Study 15153174 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole orally disintegrating tablet dispersed in water and administered orally via syringe
Number of subjects: 40
Study 15153174 — intervention group
Group type: COMPARATOR
Intervention: 15 mg intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Number of subjects: 40
Study 11557646 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide 20 mg/day
Number of subjects: 358
Study 11557646 — intervention group
Group type: COMPARATOR
Intervention: sulfasalazine 2 g/day
Number of subjects: 358
Study 9710891 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 0
Study 7835329 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal with 43 g sucrose
Number of subjects: 12
Study 7835329 — intervention group
Group type: COMPARATOR
Intervention: Breakfast cereal with 0 g sucrose (non-sweetened)
Number of subjects: 12
Study 3050005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 48
Study 3050005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29797909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Feishu (BL 13), Xinshu (BL 15), Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Geshu (BL 17), and Shenmen (HT 7) once a day, with a 2-day interval after every 5 days of treatment for 3 weeks.
Number of subjects: 128
Study 29797909 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0.4 mg or 0.8 mg) orally before sleep for 3 weeks.
Number of subjects: 128
Study 27816057 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention designed to support screening and brief intervention for problem alcohol use
Number of subjects: 81
Study 27816057 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 81
Study 26517587 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based health interventions for weight loss
Number of subjects: 207
Study 26517587 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based health interventions for diabetes self-monitoring
Number of subjects: 207
Study 26517587 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PAM score and SoC among participants in the intervention groups
Number of subjects: 207
Study 23506383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test, HbA1c, biochemical and anthropometric data
Number of subjects: 193
Study 21685640 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Exposure Therapy (VRBET)
Number of subjects: 10
Study 21685640 — intervention group
Group type: COMPARATOR
Intervention: Virtual Reality Based Exposure Therapy (VRBET) combined with cognitive therapy
Number of subjects: 10
Study 19533177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lean traction
Number of subjects: 32
Study 19533177 — intervention group
Group type: COMPARATOR
Intervention: Axial traction
Number of subjects: 32
Study 16394961 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological empowerment intervention (PEI)
Number of subjects: 38
Study 16394961 — intervention group
Group type: COMPARATOR
Intervention: Traditional strength training (TST)
Number of subjects: 38
Study 15612966 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide once daily (up to 800 microg per day)
Number of subjects: 1922
Study 15612966 — intervention group
Group type: COMPARATOR
Intervention: Budesonide twice daily (up to 800 microg per day)
Number of subjects: 1922
Study 11312481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5%)
Number of subjects: 48
Study 11312481 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 48
Study 11312481 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 48
Study 7717370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose 13‐Cis‐Retinoic Acid (80 mg daily for 6 months)
Number of subjects: 46
Study 7717370 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose 13‐Cis‐Retinoic Acid (200 mg po daily for 3 months)
Number of subjects: 46
Study 7717370 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (800 mg po daily for 3 months)
Number of subjects: 46
Study 2235346 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-100 (Z group)
Number of subjects: 178
Study 2235346 — intervention group
Group type: COMPARATOR
Intervention: L-cysteine (L group)
Number of subjects: 178
Study 631413 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (Euhypnos)
Number of subjects: 2
Study 631413 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole syrup
Number of subjects: 2
Study 31869281 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-randomized trial
Number of subjects: 0
Study 31869281 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually randomized group treatment trial
Number of subjects: 0
Study 31869281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-wedge group-randomized trial
Number of subjects: 0
Study 31869281 — intervention group
Group type: COMPARATOR
Intervention: Traditional randomized controlled trial
Number of subjects: 0
Study 31135603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 72
Study 31135603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 28611324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango leaf mouthwash
Number of subjects: 20
Study 28611324 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 20
Study 26482865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 × 500 mg/day) and E (400 IU/day)
Number of subjects: 11
Study 26482865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24486352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 100
Study 24486352 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 100
Study 22180452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg
Number of subjects: 0
Study 22180452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 25 mg
Number of subjects: 0
Study 22180452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 0
Study 22180452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22180452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (all doses)
Number of subjects: 0
Study 19566585 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 24,000 SQ-U
Number of subjects: 30
Study 19566585 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 200,000 SQ-U
Number of subjects: 30
Study 19566585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17599433 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide in the ER
Number of subjects: 281
Study 17599433 — intervention group
Group type: COMPARATOR
Intervention: Not treated with eptifibatide in the ER (Control)
Number of subjects: 281
Study 16253583 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin
Number of subjects: 50
Study 16253583 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 50
Study 16253583 — intervention group
Group type: COMPARATOR
Intervention: Both atorvastatin and pravastatin
Number of subjects: 50
Study 12010337 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister technique
Number of subjects: 0
Study 12010337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin split-thickness graft technique
Number of subjects: 0
Study 10572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine for 28 weeks
Number of subjects: 0
Study 10572352 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline for 28 weeks
Number of subjects: 0
Study 10572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine for six months
Number of subjects: 0
Study 10572352 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine for six months
Number of subjects: 0
Study 8951782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive cytoreductive treatments with chemotherapeutic agents
Number of subjects: 0
Study 8951782 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy and preventive antiplatelet therapy
Number of subjects: 0
Study 8951782 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-country, collaborative RCTs
Number of subjects: 0
Study 8951782 — intervention group
Group type: EXPERIMENTAL
Intervention: Core data and practices from multicenter trials
Number of subjects: 0
Study 1829574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of alteplase (70 mg or 80 mg if body weight >= 90 kg)
Number of subjects: 60
Study 6667627 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg slow-release salbutamol tablet
Number of subjects: 9
Study 6667627 — intervention group
Group type: COMPARATOR
Intervention: 1 standard 4 mg tablet
Number of subjects: 9
Study 6667627 — intervention group
Group type: COMPARATOR
Intervention: 2 standard 4 mg tablets
Number of subjects: 9
Study 31752952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow of 400, 800, and 1200 ml/s
Number of subjects: 10
Study 31752952 — intervention group
Group type: COMPARATOR
Intervention: Higher PEEP levels (5 and 15 cmH2O)
Number of subjects: 10
Study 31752952 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher inspiratory flow
Number of subjects: 10
Study 29797588 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-player exergame condition (n=30)
Number of subjects: 69
Study 29797588 — intervention group
Group type: COMPARATOR
Intervention: Multi-player exergame condition (n=39)
Number of subjects: 69
Study 29797588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 69
Study 26867588 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-text based weight maintenance messages and a single maintenance support phone call over 12 weeks
Number of subjects: 380
Study 26867588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 380
Study 26867588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 380
Study 25219353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 59
Study 25219353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 22882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical educators' expectations for overweight students
Number of subjects: 162
Study 22882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical educators' performance expectations for overweight students
Number of subjects: 162
Study 22882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical educators' attributions for overweight students
Number of subjects: 162
Study 22882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical educators' attitudes toward overweight students
Number of subjects: 162
Study 19603316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular syntometrine
Number of subjects: 686
Study 19603316 — intervention group
Group type: COMPARATOR
Intervention: Intravenous syntocinon
Number of subjects: 686
Study 17264952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 436
Study 17264952 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 436
Study 15041401 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS, 720 mg b.i.d.
Number of subjects: 322
Study 15041401 — intervention group
Group type: COMPARATOR
Intervention: MMF, 1000 mg b.i.d.
Number of subjects: 322
Study 11583477 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide at a dose of 200 mg daily for 4 weeks
Number of subjects: 20
Study 9845448 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcar screw placement
Number of subjects: 20
Study 9845448 — intervention group
Group type: COMPARATOR
Intervention: Conventional screw placement
Number of subjects: 20
Study 10933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2, 4 and 8 mg/70 kg)
Number of subjects: 14
Study 10933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5 and 1 mg/70 kg)
Number of subjects: 14
Study 10933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (highest dose)
Number of subjects: 14
Study 10933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 14
Study 10933340 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (all doses)
Number of subjects: 14
Study 2715471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarless gum (four pieces per day)
Number of subjects: 11
Study 2715471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vigorous mastication)
Number of subjects: 11
Study 577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg orally)
Number of subjects: 24
Study 577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine (140 mg orally)
Number of subjects: 24
Study 577876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24
Study 577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 24
Study 31279028 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole 2% ointment
Number of subjects: 21
Study 31279028 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 21
Study 31340023 — intervention group
Group type: EXPERIMENTAL
Intervention: PISCES alerts (software application for real-time clinical trial enrollment)
Number of subjects: 15626
Study 31340023 — intervention group
Group type: COMPARATOR
Intervention: Before PISCES implementation (control group)
Number of subjects: 15626
Study 31340023 — intervention group
Group type: EXPERIMENTAL
Intervention: After PISCES implementation (intervention group)
Number of subjects: 15626
Study 28535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual Physical Examination (APE) in urban elderly
Number of subjects: 3922
Study 28535772 — intervention group
Group type: COMPARATOR
Intervention: Annual Physical Examination (APE) in rural elderly
Number of subjects: 3922
Study 28535772 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with APE use in rural elderly
Number of subjects: 3922
Study 28535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with APE use in urban elderly
Number of subjects: 3922
Study 28535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly covered by Urban Resident Basic Medical Insurance (URBMI) in urban areas
Number of subjects: 3922
Study 26082611 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine orotate/olmesartan medoxomil 10/40 mg
Number of subjects: 30
Study 26082611 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate/olmesartan medoxomil 10/40 mg
Number of subjects: 30
Study 23697800 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined calcium montmorillonite clay (UPSN)
Number of subjects: 0
Study 23697800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate)
Number of subjects: 0
Study 22025998 — intervention group
Group type: EXPERIMENTAL
Intervention: Long glass fiber‐reinforced posts
Number of subjects: 100
Study 22025998 — intervention group
Group type: COMPARATOR
Intervention: Long metal screw posts
Number of subjects: 100
Study 19694343 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic formulation containing Lactobacillus Paracasei B 20160
Number of subjects: 18
Study 19694343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17021425 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml of diluted lemon juice (G4)
Number of subjects: 80
Study 17021425 — intervention group
Group type: COMPARATOR
Intervention: 250 ml of whole milk (G3)
Number of subjects: 80
Study 17021425 — intervention group
Group type: COMPARATOR
Intervention: 250 ml of water (G2)
Number of subjects: 80
Study 17021425 — intervention group
Group type: COMPARATOR
Intervention: No action (G1)
Number of subjects: 80
Study 15564189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (HCD)
Number of subjects: 693
Study 15564189 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze dressing
Number of subjects: 693
Study 10639609 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant-methionyl human neurotrophin-3 (r-metHuNT3) at doses ranging from 3 to 500 microg/kg/day
Number of subjects: 7
Study 10639609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9299802 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 36
Study 9299802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7506158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nimesulide 300 mg/day
Number of subjects: 64
Study 7506158 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac 150 mg/day
Number of subjects: 64
Study 7506158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal nimesulide 400 mg/day
Number of subjects: 64
Study 7506158 — intervention group
Group type: COMPARATOR
Intervention: Rectal diclofenac 200 mg/day
Number of subjects: 64
Study 3713394 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 22
Study 3713394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 22
Study 3713394 — intervention group
Group type: COMPARATOR
Intervention: Non-convective nystagmus
Number of subjects: 22
Study 30203153 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX/UST combination therapy
Number of subjects: 196
Study 30203153 — intervention group
Group type: COMPARATOR
Intervention: UST monotherapy
Number of subjects: 196
Study 27507876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on day 1 of every 21-day cycle) plus gefitinib (250 mg/d)
Number of subjects: 195
Study 24730621 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy with initial scaling and root planing
Number of subjects: 24
Study 24730621 — intervention group
Group type: COMPARATOR
Intervention: Surgical periodontal therapy without initial scaling and root planing
Number of subjects: 24
Study 22646067 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate oral solution
Number of subjects: 36
Study 22646067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19865076 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion HCl
Number of subjects: 54
Study 19865076 — intervention group
Group type: EXPERIMENTAL
Intervention: practical group counseling (PGC)
Number of subjects: 54
Study 19865076 — intervention group
Group type: COMPARATOR
Intervention: pill placebo
Number of subjects: 54
Study 17509314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily until stone clearance or for a maximum of 30 days)
Number of subjects: 60
Study 17509314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily until stone clearance or for a maximum of 30 days)
Number of subjects: 60
Study 17509314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 60
Study 17509314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16194582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 341
Study 16194582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 12352802 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dose and fractional three dose schedules of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73
Study 12352802 — intervention group
Group type: EXPERIMENTAL
Intervention: Three half-doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73
Study 12352802 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing regimens of polyribosylribosyl phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73